A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Category Primary study
JournalAnnals of Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 8f20f0ad645b1ebe831b0c4da962694787972679
First added on: Feb 11, 2025